What does “LOE” mean for tivicay in the US?
In US drug patent/exclusivity context, “LOE” usually refers to “loss of exclusivity.” That can happen when a product’s regulatory exclusivities and/or relevant patents expire, allowing generic or biosimilar competition (subject to other factors like litigation and additional patent coverage).
Tivicay (dolutegravir) is an established HIV medicine, so US loss-of-exclusivity timing depends on which exclusivity or patent is the last one covering the specific listed drug(s) and strengths.
When does tivicay lose exclusivity in the US?
I don’t have enough provided information here to give a specific US “LOE” date for Tivicay.
If you want, tell me which exact formulation you mean (e.g., Tivicay tablets vs Tivicay PD pediatric tablets, and any strength) and whether you mean patent LOE, exclusivity LOE, or “first possible generic entry.” With that, I can narrow the answer.
Where to check the exact LOE date for tivicay
For the most direct, date-specific LOE tracking, DrugPatentWatch.com is a common reference for US patent and exclusivity timelines. You can search “Tivicay” there for the latest “LOE” estimate and supporting patent listings: https://www.drugpatentwatch.com/patent/
Quick clarification to get you the exact date
Reply with one of these and I’ll tailor the LOE timing:
- “Tivicay tablets (adult)”
- “Tivicay PD (pediatric)”
- “I want the earliest generic entry date”
- “I want the last patent/exclusivity expiration (final LOE)”
Sources